Anthem Biosciences Limited (NSE: ANTHEM) has announced robust financial results for the second quarter and half year of FY27, showcasing significant growth and margin expansion. Consolidated revenue from operations for the quarter stood at ₹5,940 Mn, up 7.9% YoY, while EBITDA was ₹3,304 Mn, marking a 24.1% increase. The company’s profit after tax (PAT) for Q2FY27 was ₹2,115 Mn, reflecting a 21.9% rise compared to the same period last year.

Half-Year Financial Highlights

For the first half of FY27, Anthem Biosciences Limited reported consolidated revenue from operations of ₹10,123 Mn, a decrease of 7.2% YoY. However, the company’s EBITDA for H1 FY27 was ₹5,059 Mn, with margins at 46.2%. The PAT for H1 FY27 was ₹3,314 Mn, showing a 7.2% increase compared to H1 FY26.

Margin and Cost Efficiency

Anthem Biosciences Limited has demonstrated strong performance in maintaining and expanding its EBITDA and PAT margins. The company’s ability to sustain growth is attributed to strict discipline around cost efficiencies, yield optimization, and workforce productivity. This has further solidified its industry-leading margins, positioning the company well to sustain this performance throughout the year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Anthem posts a 5.8% three-month gain, but softens in the last few weeks. The PEG stands at 5.22 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 28.7% reflect exceptional pricing power and operational efficiency. The stock gives back 9.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 5.22 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.

Global Health Limited (NSE: MEDANTA), one of the largest private multi-specialty tertiary care providers in India, announced its unaudited consolidated financial results for the quarter and six-month period ending September 30, 2026. The company reported robust growth driven by significant bed additions and strong patient volumes. Notably, the company’s revenue from operations increased by 33.6% year-on-year to INR 14,690 million in Q2 FY27.

Key Financial Highlights

Operating EBITDA grew 60.2% year-on-year to INR 3,701 million with margins improving to 25.2% in Q2 FY27 compared to 21.0% in Q2 FY26. Profit after tax (PAT) stood at INR 2,191 million, up 38.3% year-on-year. The Noida hospital achieved EBITDA breakeven in Q2 FY27, within one year of commencing operations.

Operational Growth

The company added 74 new beds across the network during the quarter, with 49 beds added in Noida and 25 in Lucknow. The total census bed capacity stood at 3,115 in Q2 FY27 compared to 2,658 beds in Q2 FY26. In-patient count grew by 29.5% while out-patient count grew by 37.9% year-on-year. The occupancy rate increased to 67% compared to 64% in the same quarter last year.

Future Expansion Plans

Building on this momentum, the board approved the development of a 500-bedded super-specialty hospital in Ghaziabad, a market with strong demand for quality tertiary care. With this, the company plans to add over 3,450 beds across six greenfield projects to be executed over the next few years.

Commenting on the results, Mr. Pankaj Sahni, Group CEO and Director, said, ‘We are pleased to report strong growth in Q2 and H1 FY27, driven by robust patient volumes. We continue to deliver steady growth as we expand our bed capacity across multiple locations to meet India’s growing need for quality healthcare.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Global Health Limited

Global Health Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Global moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.08. The stock trades on brand and index weight, not on growth. The business compounds revenue at 17.2% and profits at 19.5% CAGR. That is strong double-digit growth on both counts. RSI stands at 29, well into oversold territory. Yet sellers still dominated on 21 of recent sessions versus 9 for buyers, so the pressure has not fully lifted. Revenue grows at 17.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Global Health Limited.

Max India Limited (MAXIND) has reported its financial performance for Q2FY’27, showcasing a significant revenue growth of 89% year-on-year (YoY) and a notable reduction in EBITDA loss by 55% YoY. The company’s strong performance is driven by its key segments, particularly in Residences for Seniors and Care Homes & AGEasy.

Residencies for Seniors

The Residences for Seniors segment has seen a remarkable revenue increase of 156% YoY and 35% quarter-on-quarter (QoQ). Notably, the Gurugram E360 project has achieved 100% unit sales within July 2025, and Noida Phase I handovers are underway. Sales collections for Q2FY’27 reached approximately Rs 212 crore, with E361 units selling at a velocity of 31 per month.

Care Homes & AGEasy

The Care Homes & Services revenue grew by 40% YoY and 6% QoQ, with a significant increase in occupied bed days and average revenue per occupied bed (ARPOB). AGEasy, focusing on senior-focused innovative products, reported a revenue of Rs 35 crore, marking a 1.7x YoY growth. The company has also received 8 NABH accreditations for its centres, reinforcing its position as a leader in the senior living sector.

Financial Performance

The consolidated EBITDA loss has been reduced by 55% YoY and 54% QoQ, indicating the emerging path to profitability. With a liquidity position of Rs 395 crore, Max India Limited is well-positioned to navigate future challenges and capitalize on growth opportunities.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 13.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.